Fig. 3

Mean LCSS ASBI (A), Mean LCSS-3-IGI (B), and mean Overall Impact on Normal Activities (C) of MPM patients, stratified by current treatment and by current line of therapy at time of data abstraction. Note: Patients from EU countries including France, Germany, Italy, Spain, and the UK. Error bars represent 95% confidence intervals. The MID for the LCSS ASBI is 10 points and the MID for the LCSS-3-IGI is 30 points. ASBI, average symptom burden index; BSC, best supportive care; doublet, doublet chemotherapy; LCSS, Lung Cancer Symptom Scale-Mesothelioma; LOT, line of therapy; MPM, malignant pleural mesothelioma; others, other therapies; SACT, systemic anti-cancer therapy; triplet, triplet chemotherapy; 1 L, first-line therapy; 1 L-M, first-line maintenance therapy; 2 L + SACT, SACT at second or later lines; 2 L+ BSC, BSC at second or later lines; 3-IGI, three-item global index